Expression of Prolyl-Hydroxylase-1 (PHD1/EGLN2) Suppresses Hypoxia Inducible Factor-1α Activation and Inhibits Tumor Growth

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8777-8783

  Erez, Neta ^a   Milyavsky, Michael ^a   Eilam, Raya ^a   Shats, Igor ^a   Goldfinger, Naomi ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; DNA BINDING PROTEIN; HIF1ALPHA PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PHD1 PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYLHYDROXYLASE 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL DENSITY; CELL DIVISION; CELL HYPOXIA; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME DEGRADATION; EXPERIMENTAL NEOPLASM; GENE TRANSFER; GENETICS; HUMAN; HUMAN CELL; HYPOXIA; METABOLISM; MOUSE; NUDE MOUSE; OXYGENATION; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSACTIVATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULARIZATION; XENOGRAFT;

ANIMALS; CELL DIVISION; CELL HYPOXIA; DEFEROXAMINE; DNA-BINDING PROTEINS; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROCOLLAGEN-PROLINE DIOXYGENASE; SACCHAROMYCES CEREVISIAE PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0346059600     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Semenza, G. L. HIF-1 and human disease: one highly involved factor. Genes Dev., 14: 1983-1991, 2000.
2. Sutter, C. H., Laughner, E., and Semenza, G. L. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. USA, 97: 4748-4753, 2000.
3. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA, 95: 7987-7992, 1998.
4. Safran, M., and Kaelin, W. G., Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Investig., 111: 779-783, 2003.
5. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. C. Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107: 43-54, 2001.
6. Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Gunzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., and Kaelin, W. G., Jr. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA, 99: 13459-13464, 2002.
7. Bruick, R. K., and McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science (Wash. DC), 294: 1337-1340, 2001.
8. Taylor, M. S. Characterization and comparative analysis of the EGLN gene family. Gene, 275: 125-132, 2001.
9. Oehme, F., Ellinghaus, P., Kolkhof, P., Smith, T. J., Ramakrishnan, S., Hutter, J., Schramm, M., and Flamme, I. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem. Biophys. Res. Commun., 296: 343-349, 2002.
10. Maxwell, P. H., and Ratcliffe, P. J. Oxygen sensors and angiogenesis. Semin Cell Dev. Biol., 13: 29-37, 2002.
11. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
12. Wax, S. D., Rosenfield, C., and Taubman, M. B. Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. J. Biol. Chem., 269: 13041-13047, 1994.
13. Lipscomb, E. A., Sarmiere, P. D., and Freeman, R. S. Sm-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons. J. Biol. Chem., 276: 5085-5092, 2001.
14. Seth, P., Krop, I., Porter, D., and Polyak, K. Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene, 21: 836-843, 2002.
15. Erez, N., Milyavsky, M., Goldfinger, N., Peles, E., Gudkov, A. V., and Rotter, V. Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene, 21: 6713-6721, 2002.
16. Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T., and Neckers, L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem., 273: 11995-11998, 1998.
17. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev., 14: 34-44, 2000.
18. Milyavsky, M., Mimran, A., Senderovich, S., Zurer, I., Erez, N., Shats, I., Goldfinger, N., Cohen, I., and Rotter, V. Activation of p53 protein by telomeric (TTAGGG)n repeats. Nucleic Acids Res., 29: 5207-5215, 2001.
19. Offer, H., Wolkowicz, R., Matas, D., Blumenstein, S., Livneh, Z., and Rotter, V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett., 450: 197-204, 1999.
20. Bianchi, L., Tacchini, L., and Cairo, G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res., 27: 4223-4227, 1999.
21. 2 arrest after DNA damage. Science (Wash. DC), 282: 1497-1501, 1998.
22. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res., 59: 5830-5835, 1999.
23. Semenza, G. L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell, 107: 1-3, 2001.
24. Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang, W. Q., Wotzlaw, C., Hellwig-Burgel, T., Jelkmann, W., Acker, H., and Fandrey, J. Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing. J. Cell Sci., 116: 1319-1326, 2003.
25. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16: 4604-4613, 1996.
26. Clifford, S. C., and Maher, E. R. Von Hippel-Lindau disease: clinical and molecular perspectives. Adv. Cancer Res., 82: 85-105, 2001.
27. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch, J., Pak, B., Taghavi, P., and Semenza, G. L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res., 63: 1138-1143, 2003.
28. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med., 8: (4 Suppl) S62-S67, 2002.
29. Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., and Semenza, G. L. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61: 2911-2916, 2001.
30. Koukourakis, M. I., Giatromanolaki, A., Skarlatos, J., Corti, L., Blandamura, S., Piazza, M., Gatter, K. C., and Harris, A. L. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res., 61: 1830-1832, 2001.
31. Brown, J. M. Tumor microenvironment and the response to anticancer therapy. Cancer Biol. Ther., 1: 453-458, 2002.
32. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P. M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3: 347-361, 2003.
33. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Investig., 111: 1287-1295, 2003.
34. Rosano, L., Spinella, F., Salani, D., Di Castro, V., Venuti, A., Nicotra, M. R., Natali, P. G., and Bagnato, A. Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma. Cancer Res., 63: 2447-2453, 2003.
35. Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., and Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 3: 363-375, 2003.
36. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., and Livingston, D. M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med., 6: 1335-1340, 2000.
37. Warnecke, C., Griethe, W., Weidemann, A., Jurgensen, J. S., Willam, C., Bachmann, S., Ivashchenko, Y., Wagner, I., Frei, U., Wiesener, M., and Eckardt, K. U. Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J., 17: 1186-1188, 2003.